Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InspireMD (NSPR) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for InspireMD (NSPR) over the last 16 years, with Q3 2025 value amounting to 517.28%.

  • InspireMD's EBITDA Margin fell 497700.0% to 517.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 602.87%, marking a year-over-year decrease of 1638700.0%. This contributed to the annual value of 478.0% for FY2024, which is 1372600.0% down from last year.
  • According to the latest figures from Q3 2025, InspireMD's EBITDA Margin is 517.28%, which was down 497700.0% from 732.23% recorded in Q2 2025.
  • InspireMD's EBITDA Margin's 5-year high stood at 284.86% during Q4 2021, with a 5-year trough of 749.51% in Q1 2025.
  • Its 5-year average for EBITDA Margin is 425.85%, with a median of 376.38% in 2021.
  • Its EBITDA Margin has fluctuated over the past 5 years, first soared by 20683100bps in 2021, then tumbled by -2588400bps in 2025.
  • Quarter analysis of 5 years shows InspireMD's EBITDA Margin stood at 284.86% in 2021, then tumbled by -69bps to 481.09% in 2022, then skyrocketed by 31bps to 329.81% in 2023, then tumbled by -46bps to 480.61% in 2024, then decreased by -8bps to 517.28% in 2025.
  • Its EBITDA Margin stands at 517.28% for Q3 2025, versus 732.23% for Q2 2025 and 749.51% for Q1 2025.